A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial

BACKGROUND: Neuroprotective agents have the potential to improve the outcomes of revascularisation therapies in acute ischemic stroke patients (AIS) and in those unable to receive revascularisation. Afamelanotide, a synthetic α-melanocyte stimulating hormone analogue, is a potential novel neuroprote...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanislaus, Vimal, Kam, Anthony, Murphy, Lily, Wolgen, Philippe, Walker, Gill, Bilbao, Pilar, Cloud, Geoffrey C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373257/
https://www.ncbi.nlm.nih.gov/pubmed/37496004
http://dx.doi.org/10.1186/s12883-023-03338-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373257/
https://www.ncbi.nlm.nih.gov/pubmed/37496004
http://dx.doi.org/10.1186/s12883-023-03338-9

Ejemplares similares